Professor Zhan has been deeply engaged in the basic and translational medicine research of lipid nanomedicine for a long time, and has achieved a number of innovative research results in the fields of lipid nanomedicine in vivo process and interaction mechanism with the body, personalized and accurate delivery of lipid nanomedicine in vivo, and quality control and evaluation of lipid nanomedicine. Up to now, it has applied for 23 patents, 5 PCTS, 6 licenses, 3 conversion and transfer, and published more than 100 SCI papers
Awards:2022, Youth Science Award by the Ministry of Education
2021, National Natural Science Foundation Distinguished Young Scholars Program
2019, China Pharmaceutical Association - Innovent Biologics Youth Award
2018, Outstanding Discipline Leader of the Shanghai Health and Family Planning System
2018, Daiichi Sankyo Scholarship
2017, Second Prize of the Natural Science Award by the Ministry of Education
2016, Second Prize of the Shanghai Natural Science Award
2014, Second Prize of the Science and Technology Award by the Chinese Pharmaceutical
Papers: - Wang H#,*, Lin S#, Wu X#, Jiang K, Lu H, Zhan C*. Interplay between Liposomes and IgM: Principles, Challenges, and Opportunities. Adv Sci 2023, e2301777. (IF 17.521)
- Ban Y#, Chu Y#, Pan F, Guo Z, Yang Y, Wei X, Li G, Qian J, Zhan C*, Zhang J*, Tang L*. Lipid-based Nanocarriers Enabled Oral Delivery of Oleanolic Acid Derivative DKS26 for Diabetes Management. Adv Health Mater 2023, 28, e2300639. (IF 11.092)
- Chen T#, Pan F#, Luo G#, Jiang K, Wang H, Ding T, Li W*, Zhan C*, Wei X*. Morphology-driven protein corona manipulation for preferential delivery of lipid nanodiscs. Nano Today 2022, 46, 101609. (IF 18.962)
- Wang H#, Lin S#, Wang S, Jiang Z, Ding T, Wei X, Lu Y, Yang F, Zhan C*. Folic Acid Enables Targeting Delivery of Lipodiscs by Circumventing IgM-Mediated Opsonization. Nano Lett 2022, 22, 16, 6516–6522. (IF 12.262)
- Jiang Z#, Chu Y#, Zhan C*. Protein corona: challenges and opportunities for targeted delivery of nanomedicines. Expert Opin Drug Deliv 2022, 19(7):833-846. (IF 8.129)
- Gao X*, Xu J, Yao T, Liu X, Zhang H, Zhan C*. Peptide-decorated nanocarriers penetrating the blood-brain barrier for imaging and therapy of brain diseases. Adv Drug Deliv Rev 2022, 187:114362. (IF 17.873)
- Zhang X#, Tang W#, Wen H, Wu E, Ding T, Gu J, Lv Z*, Zhan C*. Evaluation of CTB-sLip for Targeting Lung Metastasis of Colorectal Cancer. Pharmaceutics 2022, 14 (4):868. (IF 6.321)
- Jiang K, Fan X, Hu Y, Yao S, Liu Y, Zhan C*, Lu W, Wei G*. Topical instillation of cell-penetrating peptide-conjugated melphalan blocks metastases of retinoblastoma. Biomaterials 2022, 284:121493. (IF 12.479)
- Yang Y#, Long K#, Wang Y#, Li L, Shi J, Liu J, Kong L, Yu L, Ding J, Huang Z*, Wang W*, Zhan C*. NIR Light-triggered Quantitative Pulsed Drug Release. Adv Healthc Mater 2022, 11(8):e2102362. (IF 9.93)
- Tang W#, Zhang Z#, Li C#, Chu Y, Qian J, Ying T*, Lu W*, Zhan C*. Facile Separation of PEGylated Liposomes Enabled by Anti-PEG scFv. Nano Lett 2021, 21(23):10107-10113. (IF 11.19)
- Yang M, Wu E, Tang W, Qian J, Zhan C*. Interplay between nanomedicines and protein corona. J Mater Chem B 2021, 9(34):6713-6727. (IF 6.33)
- Long K#, Yang Y#, Lv W, Jiang K, Li Y, Lo A, Lam W, Zhan C*, Wang W*. Green light-triggered intraocular drug release for intravenous chemotherapy of retinoblastoma. Adv Sci 2021: e2101754. (IF 16.81)
- Tian M, Xing R, Guan J, Yang B, Zhao X, Yang J, Zhan C*, Zhang S*. A Nanoantidote Alleviates Glioblastoma Chemotoxicity without Efficacy Compromise. Nano Lett 2021, 21(12):5158-5166. (IF 11.19)
- Jiang Z, Liu J, Guan J, Wang H, Ding T, Qian J*, Zhan C*. Self-adjuvant Effect by Manipulating Bio-nano Interface of Liposome-based Nanovaccines. Nano Lett 2021, 21(11):4744-52. (IF 11.19)
- Guan J#, Wu E#, Jin P, Hou S, Qian J, Lu W, Yu B, Zhan C*. Interrogating preclinical study of liposomes: The effect of mouse strain reexamined. J Control Release 2021, 334:178-187. (IF 9.78)
- Guan J#, Chen W#, Yang M, Wu E, Qian J, Zhan C*. Regulation of in vivo delivery of nanomedicines by herbal medicines. Adv Drug Deliv Rev 2021, 174: 210-228. (IF 15.47)
- Chu Y#, Tang W#, Zhang Z*, Li C, Qian J, Wei X, Ying T, Lu W, Zhan C*. Deciphering protein corona by scFv-based affinity chromatography. Nano Lett 2021, 21 (5): 2124-2131. (IF 11.19)
DSciLab Co.,Ltd was founded in Zhangjiang Science Park, Pudong New Area, Shanghai on June 20, 2022. It is the first mRNA pharmaceutical company incubated by Fosun Health Capital. Led by Dr. Changyou Zhan, a leading expert in LNP drug delivery system and biomacromolecule drug development, we focus on building up a diverse LNP library and innovating mRNA-based treatments of clinical significance.
